Acute Reperfusion Therapy in ST-Elevation Myocardial Infarction from 1994-2003

American Journal of Medicine

Volumn 120, Issue 8, 2007, Pages

  Nallamothu, Brahmajee K ^a,b   Blaney, Martha E ^c   Morris, Susan M ^c   Parsons, Lori ^d   Miller, Dave P ^d   Canto, John G ^e,f   Barron, Hal V ^c   Krumholz, Harlan M ^g,h  

^a VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c GENENTECH INC   (United States)

^d Ovation Research Inc   (United States)

^e Watson Clinic   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g Robert Wood Johnson Clinical Scholars Program   (United States)

^h YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

Fibrinolytic therapy; Primary angioplasty; Reperfusion; ST elevation myocardial infarction

Indexed keywords

FIBRINOLYTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; FIBRINOLYTIC THERAPY; HEALTH CARE UTILIZATION; HEART INFARCTION; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RACE DIFFERENCE; REGISTER; REPERFUSION; RISK FACTOR; ST SEGMENT ELEVATION; SYMPTOM; THORAX PAIN;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMORBIDITY; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; ODDS RATIO; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY INDICATORS, HEALTH CARE; REGISTRIES; THROMBOLYTIC THERAPY; UNITED STATES;

EID: 34547580182     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.01.028     Document Type: Article

References (28)

1. Williams S.C., Schmaltz S.P., Morton D.J., et al. Quality of care in U.S. hospitals as reflected by standardized measures, 2002-2004. N Engl J Med 353 (2005) 255-264
2. Jha A.K., Li Z., Orav E.J., and Epstein A.M. Care in U.S. hospitals-the Hospital Quality Alliance program. N Engl J Med 353 (2005) 265-274
3. Williams D.O. Treatment delayed is treatment denied. Circulation 109 (2004) 1806-1808
4. Barron H.V., Bowlby L.J., Breen T., et al. Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. Circulation 97 (1998) 1150-1156
5. Rogers W.J., Canto J.G., Lambrew C.T., et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 36 (2000) 2056-2063
6. Eagle K.A., Goodman S.G., Avezum A., et al. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 359 (2002) 373-377
7. Hasdai D., Behar S., Wallentin L., et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 23 (2002) 1190-1201
8. Every N.R., Frederick P.D., Robinson M., et al. A comparison of the National Registry of Myocardial Infarction 2 with the Cooperative Cardiovascular Project. J Am Coll Cardiol 33 (1999) 1886-1894
9. Krumholz H.M., Anderson J.L., Brooks N.H., et al. ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-Elevation Myocardial Infarction). Circulation 113 (2006) 732-761
10. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343 (1994) 311-322
11. Boersma E., Maas A.C., Deckers J.W., and Simoons M.L. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 348 (1996) 771-775
12. Melandri G. The obsession with primary angioplasty. Circulation 108 (2003) e162
13. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361 (2003) 13-20
14. Gurwitz J.H., Gore J.M., Goldberg R.J., et al., National Registry of Myocardial Infarction. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. Ann Intern Med 124 (1996) 283-291
15. Canto J.G., Allison J.J., Kiefe C.I., et al. Relation of race and sex to the use of reperfusion therapy in Medicare beneficiaries with acute myocardial infarction. N Engl J Med 342 (2000) 1094-1100
16. Vaccarino V., Rathore S.S., Wenger N.K., et al. Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002. N Engl J Med 353 (2005) 671-682
17. Krumholz H.M., Murillo J.E., Chen J., et al. Thrombolytic therapy for eligible elderly patients with acute myocardial infarction. JAMA 277 (1997) 1683-1688
18. Ayanian J.Z., Hauptman P.J., Guadagnoli E., et al. Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med 331 (1994) 1136-1142
19. Alter D.A., Ko D.T., Newman A., and Tu J.V. Factors explaining the under-use of reperfusion therapy among ideal patients with ST-segment elevation myocardial infarction. Eur Heart J 27 (2006) 1539-1549
20. Cox D.A., Rogers W.J., Aguirre F.V., et al., The Thrombolysis in Myocardial Infarction Investigators. Effect on outcome of the presence or absence of chest pain at initiation of recombinant tissue plasminogen activator therapy in acute myocardial infarction. Am J Cardiol 73 (1994) 729-736
21. Canto J.G., Shlipak M.G., Rogers W.J., et al. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA 283 (2000) 3223-3229
22. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 44 (2004) 671-719
23. Mehta R.H., Granger C.B., Alexander K.P., et al. Reperfusion strategies for acute myocardial infarction in the elderly: benefits and risks. J Am Coll Cardiol 45 (2005) 471-478
24. Krumholz H.M., Pasternak R.C., Weinstein M.C., et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 327 (1992) 7-13
25. Lee D.S., Tu J.V., Juurlink D.N., et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 294 (2005) 1240-1247
26. Ko D.T., Mamdani M., and Alter D.A. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 291 (2004) 1864-1870
27. Parker A.B., Naylor C.D., Chong A., and Alter D.A. Clinical prognosis, pre-existing conditions and the use of reperfusion therapy for patients with ST segment elevation acute myocardial infarction. Can J Cardiol 22 (2006) 131-139
28. Shlipak M.G., Lyons W.L., Go A.S., et al. Should the electrocardiogram be used to guide therapy for patients with left bundle-branch block and suspected myocardial infarction?. JAMA 281 (1999) 714-719